Risks from Breathing Elevated Oxygen
INTRODUCTION: Effects of breathing gas with elevated oxygen partial pressure (Po2) and/or elevated inspired oxygen fraction (FIo2) at sea level or higher is discussed. High FIo2 is associated with absorption problems in the lungs, middle ear, and paranasal sinuses, particularly if FIo2 > 80% and...
Gespeichert in:
Veröffentlicht in: | Aerospace medicine and human performance 2019-12, Vol.90 (12), p.1041-1049 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | INTRODUCTION: Effects of breathing gas with elevated oxygen partial pressure (Po2) and/or elevated inspired oxygen fraction (FIo2) at sea level or higher is discussed. High FIo2 is associated with absorption problems in the
lungs, middle ear, and paranasal sinuses, particularly if FIo2 > 80% and small airways, Eustachian tubes, or sinus passages are blocked. Absorption becomes faster as cabin altitude increases. Pulmonary oxygen toxicity and direct oxidative injuries, related to elevated
Po2, are improbable in flight; no pulmonary oxygen toxicity has been found when Po2 < 55 kPa [418 Torr; 100% O2 higher than 15,000 ft (4570 m)]. Symptoms with Po2 of 75 kPa [520 Torr; 100% O2 at 10,000 ft (3050 m)] were reported after
24 h and the earliest signs at Po2 of 100 kPa (760 Torr, 100% O2 at sea level) occurred after 6 h. However, treatment for decompression sickness entails a risk of pulmonary oxygen toxicity. Elevated Po2 also constricts blood vessels, changes blood pressure
control, and reduces the response to low blood sugar. With healthy lungs, gas transport and oxygen delivery are not improved by increasing Po2. Near zero humidity of the breathing gas in which oxygen is delivered may predispose susceptible individuals to bronchoconstriction.Shykoff
BE, Lee RL. Risks from breathing elevated oxygen. Aerosp Med Hum Perform. 2019; 90(12):1041-1049. |
---|---|
ISSN: | 2375-6314 2375-6322 |
DOI: | 10.3357/AMHP.5393.2019 |